Health Care • Biotechnology: Pharmaceutical Preparations
$0.73 ▼ -0.04
(-5.52%)
MKT CAP: $10.9M • VOL: 233.9K
52W L $1 52W H $4
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
LTRN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$18.0M | -$22.2M | -$17.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$17.1M | -$20.8M | -$16.0M |
| EBITDA (Normalized) | -$18.0M | -$22.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.7M | -$17.8M | -$14.3M |
| Capital Expenditures (CapEx) | $1.7K | $12.6K | — |
| Free Cash Flow (FCF) | -$15.7M | -$17.8M | -$14.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.4M | $7.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.5M | $21.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LTRN.